Despite this, multiple studies have indicated that combining the treatment of anti-angiogenesis agents and PD-1/PD-L1 antibodies achieves synergistic effects on different types of cancer (15, 16), bringing hope to patients with advanced cancer. The gene discussed is PDCD1; the disease is cancer.